Nefersil Fast

Quick links to important sections

Nefersil Fast

Method of action: Analgesic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nefersil Fast

Quick Facts

Property Description
Active ingredient Clonixin Lysine (Lysine Clonixinate)
Form Oral Capsule (designed for rapid absorption)
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID) and Analgesic
General purpose Relief of pain, inflammation, and fever
Origin Synthetic compound (anthranilic acid derivative)

What Type of Medicine Is Nefersil Fast?

Nefersil Fast is a pharmaceutical product, clinically recognized as a Non-steroidal Anti-inflammatory Drug (NSAID) and an Analgesic. Its active substance, Clonixin Lysine, is structurally defined as an anthranilic acid derivative, placing it within a specific family of NSAID compounds. This pharmacological classification reflects its function as a cyclooxygenase inhibitor. The medication operates as a dual-purpose therapeutic agent, with its general use focused on addressing both pain and the underlying inflammatory process.

Active Ingredient and "Fast" Formulation

The core of this medicine is the single active component, Clonixin Lysine, which is delivered in an oral capsule format. A key differentiating feature is the inclusion of the Lysine salt, which is specifically chosen to enhance the solubility of the Clonixin molecule. The brand name includes the designation "Fast," a term referring to the unique formulation engineered for notably rapid dissolution and absorption within the digestive system. This design choice aims to accelerate the time required for the active substance to achieve systemic circulation, thereby optimizing the onset of the analgesic effect, a benefit particularly relevant in the management of acute discomfort.

The General Purpose of Clonixin Lysine

The primary utility of the drug is to provide integrated analgesic and anti-inflammatory relief. Its mechanism is founded on interfering with the synthesis of prostaglandins, the chemical mediators crucial for initiating pain and inflammation. This action provides general therapeutic benefits for conditions where inflammation is accompanied by pain. Additionally, Clonixin Lysine is clinically recognized for its antipyretic effect, meaning its purpose extends to the reduction of elevated body temperature, positioning its function as a comprehensive tool for the simultaneous reduction of pain, swelling, and fever associated with the body's inflammatory response.

Regulatory References

  1. Clonixin Drug Monograph

What side effects are possible with Nefersil Fast?

Official Safety Profile and Adverse Reactions

Regulatory documents classify the safety profile of Nefersil Fast (Nimesulide) by the potential for both common and serious adverse reactions, which is typical for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with additional specific risks.


Key Serious Adverse Reactions

  • Hepatotoxicity: The most serious and defining risk is the potential for liver injury, which may progress to acute liver failure, requiring transplantation or leading to death. This risk is subject to mandatory labeling and use restrictions by regulatory bodies.
  • Gastrointestinal Events: Like other NSAIDs, the medicine is associated with a risk of serious gastrointestinal complications, including bleeding, ulceration, or perforation of the stomach or intestines.
  • Cardiovascular Thrombotic Events: An increased risk of serious cardiovascular events, such as myocardial infarction (heart attack) and stroke, has been documented.

Adverse Reaction Categories

Adverse reactions are classified by frequency (e.g., Common, Uncommon, Rare) and System-Organ Class (SOC) in official product information, including the Hepatobiliary, Gastrointestinal, and Cardiovascular systems, as well as the Nervous System and Skin.

Regulatory Restrictions and Contraindications

Due to its established safety profile, the medicine is subject to strict limitations:

  • Duration: Use is generally limited by regulators to a maximum of 15 days of continuous treatment.
  • Line of Treatment: It is often restricted to use as a second-line treatment option.
  • Contraindications: The medicine is strictly forbidden (contraindicated) for patients with severe pre-existing conditions, including severe hepatic impairment, severe heart failure, active gastrointestinal bleeding or ulceration, or severe renal impairment, as these conditions significantly increase the safety risk.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Nefersil Fast (Clonixin Lysine) overdose is based on the documented toxicological effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs). An overdose may be asymptomatic or initially present with minor, self-limiting gastrointestinal symptoms such as nausea, vomiting, stomach pain, or diarrhea. Central nervous system effects, including drowsiness, lethargy, or dizziness, may also be documented.

Severe Manifestations and Emergency Actions

Massive ingestions are associated with potentially life-threatening systemic outcomes. These severe regulatory documented manifestations include gastrointestinal hemorrhage, acute renal failure, convulsions (seizures), and coma. Cardiovascular effects, such as low blood pressure (shock), may also be observed. Older individuals and those with pre-existing kidney issues may face a higher risk for these severe complications.

Immediate medical attention or contacting a Poison Control Center is required for any suspected overdose. Emergency medical help must be sought if the patient exhibits mental status changes, unstable vital signs, sudden weakness, or slurred speech.

Management Overview Regulatory Statement
Antidote Status No specific antidote is known for this toxicity.
Clinical Management Management is entirely symptomatic and supportive.
Monitoring Hospital monitoring of vital signs and laboratory parameters is typically required for symptomatic patients.

Therapeutic Uses of Nefersil Fast

What Nefersil Fast Treats: Main Uses and Benefits

The core therapeutic utility of Nefersil Fast is applied across domains where additional symptomatic support is needed, focusing on symptoms related to inflammatory or irritative states and where timely symptomatic assistance is relevant. Its use is recognized across acute therapeutic contexts.

The medication is commonly used across conditions presenting with localized discomfort, offering supportive relief for conditions such as chronic arthritic pain (like osteoarthritis), musculoskeletal aches, renal colic, and pronounced menstrual pain (dysmenorrhea). It also supports symptom management during acute, moderate migraine headaches and helps to reduce fever when the pain is linked to a febrile, inflammatory process.

In these scenarios, the medication is applied when symptoms create noticeable physiological strain. “This application may assist with improving day-to-day comfort and contributes to maintaining functional stability during periods of heightened symptoms.” The primary goal is to contribute to easing the overall symptom load.


Quick Fact: Relief for Pain and Inflammation

Property Description
Primary Therapeutic Benefit Symptomatic relief of pain and inflammation
Symptom Focus Acute pain, chronic joint aches, fever
Key Scenarios Post-trauma, episodic attacks (migraine), chronic joint disorders
Patient Benefit May assist with maintaining stability during difficult episodes

Eligibility and Restrictions for Use

Eligibility for Nefersil Fast (Clonixin Lysine)

The regulatory profile for Nefersil Fast, an NSAID, defines population eligibility based on absolute prohibitions and use limitations.

Population Status Regulatory Classification
Use Allowed Adults (18 years and older) whose clinical profile is clear of contraindications.
Use Not Established Pediatric patients (children and adolescents).
Use Not Recommended Lactating/Breastfeeding mothers; an alternate drug is preferred due to insufficient safety data.

Absolute Contraindications (Must Not Use)

Official labeling mandates that the medicine must not be used by patients with:

  • Known hypersensitivity to Clonixin Lysine or any other Non-steroidal Anti-inflammatory Drug (NSAID).
  • Active gastrointestinal bleeding, peptic ulceration, or perforation.
  • Severe hepatic (liver) or renal (kidney) impairment.
  • Third trimester of pregnancy.

Age and Condition Restrictions

Use is conditional for older adults (geriatric population) and patients with mild to moderate organ impairment, requiring caution. Use during the first and second trimesters of pregnancy is restricted and generally advised only when strictly necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nefersil Fast (Clonixin Lysine) is an NSAID, and its interaction profile is defined by official regulatory documentation focusing on two primary concerns: additive risk of bleeding and altered drug concentrations.

Documented Pharmacological Interactions

Interacting Product Category Officially Documented Interaction Outcome
Other NSAIDs and High-Dose Aspirin Co-administration is formally contraindicated due to an additive risk of gastrointestinal damage and renal impairment.
Anticoagulants and Antiplatelet Agents Documented increased risk and severity of hemorrhage or bleeding events.
SSRIs, SNRIs Interaction documentation notes an increased risk of gastrointestinal bleeding.
Lithium, Methotrexate, Digoxin The drug reduces the renal clearance of these medicines, a pharmacokinetic effect that increases their plasma concentrations and potential for toxicity.
Anti-hypertensive Drugs (ACE Inhibitors, Diuretics) Official warnings state that the therapeutic effect of these agents may be diminished, compromising blood pressure control.

Substance and Population Restrictions

Consumption of Alcohol is documented to increase the severity and risk of gastrointestinal mucosal damage and bleeding. Furthermore, the official prescribing information notes that interaction risks are heightened in patient populations with pre-existing renal or hepatic impairment, as these conditions compromise drug clearance and magnify the potential for adverse interactions.

Mechanism of Action

How Nefersil Fast Works

Molecular Targeting: COX Enzyme Inhibition

The mechanism of Nefersil Fast centers on the Clonixin molecule's ability to act as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This interaction prevents the COX enzymes from converting arachidonic acid into prostaglandins and other eicosanoids, thereby blocking the central pathway responsible for the physiological production of these mediators.

Pathophysiological Cascade Modulation

By suppressing prostaglandin synthesis, the drug modulates two primary physiological responses: peripheral signal sensitization and central thermoregulation. The peripheral reduction of PGE₂ reduces the biochemical sensitization of peripheral nociceptors, while the central reduction of PGE₂ within the hypothalamus affects the signaling that controls the central thermoregulatory set-point.

Mechanism Onset Optimization

The overall efficiency of the COX inhibition mechanism is enhanced by the specialized Lysine salt formulation. This modification optimizes the molecule's delivery speed (a pharmacokinetic factor), facilitating the accelerated initiation of the inhibitory mechanism upon reaching the COX targets.

Dosage and Administration Information

How to Use Nefersil Fast: Official Administration Guidelines

Nefersil Fast (Clonixin Lysine) is used according to specific instructions established to ensure proper and standardized administration. These guidelines focus exclusively on the correct route, dosage, and frequency for the medicine.


Administration and Dosage

Feature Official Instruction Summary
Primary Route Oral administration, using the capsule or tablet formulation.
Secondary Route The active ingredient, Clonixin, is approved for intravenous (IV) or intramuscular (IM) use in clinical settings for acute pain management.
Standard Oral Dose The typical adult dose ranges from 125 mg to 300 mg per administration.
Frequency Dosing is typically restricted to a maximum of three times a day (TID). A minimum interval of 8 hours must be maintained between subsequent doses to control total daily intake.

Procedural and Contextual Instructions

The oral capsule should be swallowed whole. Regulatory documents indicate that the medicine can generally be taken without regard to meals.

  • Duration: Nefersil Fast is intended for short-term symptomatic use only, typically limiting the continuous treatment course to a specific number of days, such as seven to ten days, or as determined by the duration of the acute symptoms.
  • Population Adjustments: Official prescribing information requires dose adjustment and careful monitoring for patients who have impaired renal (kidney) or hepatic (liver) function. Using the lowest effective dose for the shortest duration is generally recommended in these populations.

These official instructions define the standardized usage protocol, ensuring that the dose, frequency, and duration of use adhere strictly to the constraints established for the active ingredient.

Recent Clinical Evidence

Nefersil Fast: Recent Clinical Evidence


Evidence for Use in Acute Pain Models

Research has explored Clonixin Lysine (the active ingredient in Nefersil Fast) using randomized controlled trials (RCTs) and active comparator studies. The active ingredient was evaluated in research settings involving acute post-surgical pain (e.g., dental procedures), acute visceral pain (e.g., renal colic), and acute migraine attacks. Studies examined outcomes related to physical discomfort and changes in symptom intensity over short intervals. Trial findings describe patterns observed across these acute pain conditions. For migraine, data show patterns related to measurements taken for patients with moderate headache intensity attacks that varied compared to severe attacks. Research in these contexts is primarily limited to short, acute episodes.


Musculoskeletal and Chronic Pain Studies

For acute musculoskeletal pain (e.g., low back pain), studies was evaluated in active comparator trials. Evidence is limited for these conditions because some data showing symptom change patterns were derived from studies involving a combination product, making it challenging to evaluate the single active ingredient. Regarding chronic inflammatory joint conditions, research explores the pharmacological classification of the active ingredient as an NSAID, which has established research protocols for chronic pain domains.


Research Gaps and Uncertainty

The majority of research was observed in settings focused on acute changes, meaning follow-up durations were limited (a few hours up to one week). Consequently, long-term effects are not fully established. Data for certain groups remain insufficient, with little specific evidence available regarding the use of the active ingredient in older adults or those with comorbidities. Comparative evidence is lacking for some indications, and certainty remains low for long-term chronic management.

Key Studies & References World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (To support existence of clinical trial evidence)

Frequently Asked Questions (FAQ)

Common questions about Nefersil Fast (FAQ)


Q: Why is it called 'Fast'?

A: The 'Fast' designation refers to the specific formulation of the active drug as a Lysine salt. Official documents describe this modification as optimizing the molecule's absorption speed, which is described as facilitating an accelerated initiation of the drug's mechanism of action.


Q: Are there any major food or drink restrictions when taking Nefersil Fast?

A: Official instructions state that the medicine can generally be taken without regard to meals. However, regulatory information specifically documents that consuming alcohol can increase the severity and risk of damage and bleeding in the gastrointestinal lining.


Q: How long does it usually take for Nefersil Fast to start working?

A: The formulation is described in regulatory documents as promoting an accelerated initiation of the mechanism of action. However, a specific time for the onset of symptom relief is not consistently defined in the core regulatory summary documents.


Q: Is Nefersil Fast known to interact with alcohol?

A: Yes, official warnings document an increased risk. Consumption of alcohol is noted to increase the severity and risk of mucosal damage and bleeding in the gastrointestinal tract.


Q: What is the general expectation for how long the effects of Nefersil Fast last?

A: The official dosing frequency provides an indication of the expected duration of effect. Regulatory documents typically restrict dosing to a maximum of three times a day (TID), requiring a minimum interval of 8 hours between doses to control the total daily intake.


Q: What does official guidance say about taking Nefersil Fast on an empty stomach?

A: Official prescribing information indicates that the oral form can generally be taken without regard to meals.


Q: Does Nefersil Fast contain aspirin?

A: Official product information lists Clonixin Lysine as the active ingredient. Aspirin is not listed as an active or inactive ingredient in this medicine, though its use with high-dose aspirin is contraindicated (forbidden).


Q: Can I take Nefersil Fast if I have kidney issues?

A: Official documents require careful monitoring and potential dose adjustment for patients with impaired renal (kidney) function. However, the medicine is strictly forbidden (contraindicated) for patients with severe renal impairment due to the heightened safety risk.


Q: Is Nefersil Fast a painkiller?

A: The medicine is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is described in regulatory documents as being used for the management of acute pain.


Q: Can older adults use Nefersil Fast?

A: Older adults are listed in official documents as a population requiring careful monitoring or potential dose adjustment, particularly due to the chance of compromised renal or hepatic function. Specific research evidence for this group remains limited.


Q: What happens if I miss a dose of Nefersil Fast?

A: While not an explicit instruction in the core text, official guidance generally indicates that a missed dose should not be doubled. Information typically advises taking the next dose at the regular time.


Q: Is Nefersil Fast safe to use while pregnant?

A: Regulatory guidance for NSAIDs, including this drug, often states that use is not recommended or contraindicated during specific stages of pregnancy, particularly the third trimester. The official guidance often notes that an alternate drug is preferred while nursing.


Q: Can people with high blood pressure use Nefersil Fast?

A: Official warnings note that this medicine may diminish the therapeutic effect of certain anti-hypertensive drugs (medicines for high blood pressure), which could compromise blood pressure control. Regulatory warnings suggest that use requires specific risk assessment and monitoring.


Q: Does Nefersil Fast interact with common vitamins or supplements?

A: Official documents list interactions with specific drug classes, such as anticoagulants and other NSAIDs. They do not typically list specific warnings for common vitamins or supplements, implying no major regulatory-mandated warnings exist.


Q: Is it possible to become dependent on Nefersil Fast?

A: The drug is not classified as a controlled substance, and the official labeling does not typically include warnings about dependency or abuse potential for this class of medicine (NSAIDs).


Q: Are there any long-term effects of taking Nefersil Fast regularly?

A: Regulatory documents limit the continuous use of this medicine to a short duration, such as a maximum of 15 days, due to safety concerns. The official safety profile documents serious risks, including potential liver injury and gastrointestinal complications, which are associated with its use.


Q: Is it normal to feel tired after taking Nefersil Fast?

A: Adverse reaction lists for NSAIDs often include nervous system effects. Symptoms such as dizziness, somnolence (drowsiness), or fatigue are potential side effects that may be listed in the full official safety profile.


Q: What kind of allergies might prevent someone from taking Nefersil Fast?

A: The medicine is strictly forbidden (contraindicated) for patients with known hypersensitivity or allergic reactions to the active substance (Clonixin Lysine). Official warnings also typically include a contraindication for patients with asthma or allergic-type reactions after taking aspirin or other NSAIDs.


Q: Do official sources describe Nefersil Fast as a prescription or over-the-counter medicine?

A: The regulatory status (whether it is prescription-only or available over-the-counter) is defined by the government health authority in each country where the product is licensed. This status is part of the drug's official authorization.


Q: Is Nefersil Fast suitable for children?

A: Official product information includes a dedicated section on 'Pediatric Use' that specifies whether the drug's safety and effectiveness have been established for children or if its use is restricted in this population.


Q: How is the 'fast' version chemically different from the standard drug?

A: The active ingredient is defined in the official composition as a Clonixin-Lysine salt. This specific salt formulation is the chemical difference that sets it apart from other formulations of the Clonixin molecule.


Q: What ingredients are in Nefersil Fast besides the main active component?

A: Official product documents list the complete composition, which includes the active component (Clonixin Lysine) and all inactive ingredients, which are known as excipients.


Q: Are headaches a potential side effect of Nefersil Fast?

A: Headache is a commonly reported adverse effect for many Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It would be documented under the Nervous System category in the official adverse reactions section of the product labeling.


Q: What does the patient information leaflet say about stopping Nefersil Fast?

A: Since the medicine is intended for short-term symptomatic use (e.g., maximum 15 days), the official guidance states that use is intended to be stopped after the acute symptoms resolve or after the maximum stated duration is reached.


Q: Can people with liver issues take Nefersil Fast?

A: Official documents require careful monitoring and potential dose adjustment for patients with impaired hepatic (liver) function. However, the medicine is strictly forbidden (contraindicated) for patients with severe hepatic impairment due to the significant risk of liver injury.


Q: Does Nefersil Fast affect sleep?

A: Adverse reaction lists for NSAIDs often include Nervous System effects such as insomnia (trouble sleeping) or somnolence (drowsiness). These effects are documented as potential side effects that could affect sleep patterns.


Q: What is Nefersil Fast approved for in different countries?

A: The specific indication (the officially approved use) for Nefersil Fast is explicitly defined by the regulatory authority in each separate jurisdiction where the medicine is licensed for use.


Q: Does using Nefersil Fast affect laboratory test results?

A: Official labeling includes a dedicated section to document any known interference. This section specifies if the drug is known to affect the results of specific laboratory or diagnostic tests.


Q: Is Nefersil Fast available as different forms, like tablets or liquid?

A: Official regulatory documents explicitly specify all authorized dosage forms. These may include formulations such as capsules, tablets, or oral suspensions/liquid formulations, in addition to forms for use in clinical settings.


Q: Can people with asthma or breathing problems use Nefersil Fast?

A: Official warnings typically contraindicate (forbid) the use of this medicine in patients with asthma or other breathing issues, particularly if they have a history of reactions to aspirin or other NSAIDs, due to the risk of inducing bronchospasm.


Q: Can you drive or operate machinery after taking Nefersil Fast?

A: Official product information includes warnings regarding potential effects on the ability to drive or operate machinery. Official warnings are provided because certain adverse effects, such as dizziness or drowsiness, may be experienced.


Q: Are there different strengths of Nefersil Fast available?

A: The official regulatory document specifies all authorized strengths that are commercially available to patients. These official strengths typically fall within the established dosing range.


Q: Does Nefersil Fast treat the cause or just the symptoms?

A: The drug's official mechanism is defined as modulating pain and fever signaling. The mechanism of action means it is indicated in official documents for symptomatic use.


Q: Is Nefersil Fast considered a controlled substance?

A: Regulatory agencies classify controlled substances based on their potential for abuse or dependence. The active ingredient in this medicine is not classified as a controlled substance in major jurisdictions.

How should Nefersil Fast be stored and disposed of?

How to Store and Dispose of Nefersil Fast? — Official Regulatory Information

The required storage and disposal profile for this medicine is strictly defined by regulatory documents to maintain drug stability and ensure safety.

Storage & disposal scope Requirements from Official Labeling
Labeled storage temperature requirements: Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with permitted excursions.
Light/moisture protection requirements: Protect the capsules from excessive moisture and humidity.
Packaging-related storage rules (if applicable): Keep Nefersil Fast in its original container and do not use if the blister is compromised.
Disposal instructions (as documented in government sources): Dispose of unused or expired product according to pharmaceutical take-back programs or local environmental regulations.
Child-protection storage requirements (if stated): Keep this medicine out of the sight and reach of children and pets at all times.

Official Storage and Disposal Statements:

  • Store in the original container to maintain environmental protection.
  • Do not dispose of the medicine by flushing it down a toilet or pouring it into a drain unless specifically instructed by the label.
  • Do not keep outdated medicine or medicine no longer needed past its expiration date.

This structure strictly summarizes how regulatory documents define the required storage environment and the official procedures for discarding the product safely.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nefersil Fast found in:

A-Z Index: